Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer - Supplementary Material

Table S1: The optimal range of drug-likeness parameters followed by 95% of approved drugs

Figure S1: 2D visualization of binding postures of E4 inhibitor with MYOF

mass spec data for compounds A1-E4

Response letter